Hyped Malaria Drug Not Showing Much Effect at One Paris Hospital
(Bloomberg) --
Hydroxychloroquine, the malaria medicine that some doctors have been trying as a treatment against Covid-19, hasn't shown encouraging results so far at France's Pitie Salpetriere hospital.
“We've used it a fair bit because it was one of the hopes,” Eric Caumes, head of infectious diseases at the Paris hospital, said on BFM TV. “But we don't have the impression that there's spectacular efficacy. It's even probably not effective.” Caumes said he would have more formal data around the end of the week.
U.S. President Donald Trump touted the medicine as promising to curb the Covid-19 pandemic, fueling optimism and prompting some hospitals to stockpile it, but there's no conclusive evidence that it works against the new coronavirus.
Hydroxychloroquine showed promising results in one small study in France, but its methodology has been challenged. In another small trial in China, the drug was no more effective than conventional care.
For now, “we have more studies showing it doesn't work than studies showing it does,” Caumes said.
Pitie Salpetriere was rated France's best hospital in a 2020 Newsweek ranking.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.